Neha Krishnamohan - Feb 10, 2023 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Signature
/s/ Mark A. Meltz, attorney in fact
Stock symbol
KNTE
Transactions as of
Feb 10, 2023
Transactions value $
$0
Form type
4
Date filed
2/14/2023, 04:00 PM
Previous filing
Dec 2, 2022
Next filing
Mar 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Employee Stock Option (right to buy) Award $0 +215K $0.00 215K Feb 10, 2023 Common Stock 215K $6.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date.